Related Experiment Video
Updated: Apr 17, 2026

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
Isoeugenol Inhibits Growth, Migration, and Invasion in Colorectal Cancer Cells With Distinct Molecular
Zih-Shuan Liou1, Chih-Chun Kuo2, Chien-Chih Yeh3,4
1Department of Life Sciences, National Central University, Taoyuan, Taiwan.
Abstract:
Colorectal cancer (CRC) is the second common cause of cancer death in the world and its development can be regulated by herbal compounds. Unfortunately, little information is known about the signal pathways of Piper betle isoeugenol in CRC cells (CRCCs). Using three CRC cell lines (SW480, SW620, and HCT116) that represent different molecular characteristics and serve as in vitro models of CRC progression, we found that isoeugenol inhibited cell growth. Wound healing and Boyden chamber assays indicated that isoeugenol inhibited the migration and invasion in CRCCs. Mechanistically, isoeugenol suppressed key regulators of cell cycle progression and epithelial-mesenchymal transition (EMT), including pAKT, CDK4, CDK6, cyclin D1, N-cadherin, and Snail, while increasing the levels of pAMPK, pJNK, pp38 MAPK, and E-cadherin. Cell line-specific modulation of CDK2, cyclin D3, p21, p27, and pERK proteins was also observed. Furthermore, isoeugenol inhibited the enzymatic activities of MMP-2 and MMP-9. Pharmacological inhibition of AMPK or p38 antagonized isoeugenol-suppressed cell growth, migration, invasion, and associated signaling events. In conclusion, these data suggest that isoeugenol may inhibit CRCC growth, migration, and invasion through activations of AMPK and p38 MAPK pathways and modulating pathways involved in cell cycle regulation and EMT.
Insights
Piper betle isoeugenol inhibits colorectal cancer cell growth, migration, and invasion. These effects are mediated by activating AMPK and p38 MAPK pathways, impacting cell cycle and EMT regulation.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide.
- Herbal compounds show potential in regulating CRC development, but specific pathways remain underexplored.
- Piper betle isoeugenol's role in CRC cells (CRCCs) signaling is largely unknown.
Purpose of the Study:
- To investigate the effects and underlying mechanisms of Piper betle isoeugenol on colorectal cancer cell lines.
- To elucidate the signal pathways modulated by isoeugenol in CRCCs.
Main Methods:
- Utilized three distinct CRC cell lines (SW480, SW620, HCT116) as in vitro models.
- Performed wound healing and Boyden chamber assays to assess cell migration and invasion.
- Analyzed key proteins involved in cell cycle regulation, epithelial-mesenchymal transition (EMT), and matrix metalloproteinases (MMPs).
- Investigated the role of AMPK and p38 MAPK pathways via pharmacological inhibition.
Main Results:
- Isoeugenol significantly inhibited CRCC growth, migration, and invasion.
- Isoeugenol suppressed cell cycle regulators (e.g., pAKT, CDK4/6, cyclin D1) and EMT markers (e.g., N-cadherin, Snail).
- Isoeugenol increased levels of pAMPK, pJNK, pp38 MAPK, and E-cadherin, and inhibited MMP-2/9 activity.
- AMPK or p38 MAPK inhibition counteracted the anti-cancer effects of isoeugenol.
Conclusions:
- Isoeugenol demonstrates potent anti-cancer properties against colorectal cancer cells in vitro.
- Isoeugenol exerts its effects by activating AMPK and p38 MAPK pathways.
- Isoeugenol modulates critical pathways regulating cell cycle progression and epithelial-mesenchymal transition, offering potential therapeutic strategies for CRC.
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Cancer Cell Migration through Invadopodia
Mitogens and the Cell Cycle
Tumor Progression
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

